GlobeNewswire by notified

Cargotec Corporation: Share Repurchase 28.2.2024

Share
CARGOTEC CORPORATION, STOCK EXCHANGE RELEASE, 28 FEBRUARY 2024 AT 6.30 PM (EET)
CARGOTEC CORPORATION: SHARE REPURCHASE 28.2.2024
In the Helsinki Stock Exchange
Trade date          28.2.2024
Bourse trade        Buy
Share                 CGCBV
Amount            6 000Shares
Average price/ share   62,0638EUR
Total cost           372 382,80EUR
Cargotec Corporation now holds a total of 547 043 shares
including the shares repurchased on 28.2.2024
On behalf of Cargotec Corporation
Nordea Bank Oyj
Janne Sarvikivi          Sami Huttunen



For further information, please contact:

Aki Vesikallio, Vice President, Investor Relations, tel. +358 40 729 1670

Cargotec (Nasdaq Helsinki: CGCBV) enables smarter cargo flow for a better everyday with its leading cargo handling solutions and services. Cargotec's business areas Kalmar, Hiab and MacGregor are pioneers in their fields. Through their unique position in ports, at sea and on roads, they optimise global cargo flows and create sustainable customer value. Cargotec has signed the United Nations Global Compact Business Ambition for 1.5°C. The company's sales in 2023 totalled approximately EUR 4.6 billion and it employs around 11,400 people. www.cargotec.com

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis17.4.2024 07:15:00 CEST | Press release

Continuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing multiple sclerosis (RMS) in an analysis of the ALITHIOS open-label extension study1 Similar efficacy outcomes were demonstrated in a separate analysis of continuous Kesimpta treatment for up to six years in the overall ALITHIOS study population2 Switch from teriflunomide to Kesimpta resulted in significant improvements across several efficacy outcomes such as annualized relapse rate and MRI lesion activity in both analyses1,2 Treatment with Kesimpta for up to six years continues to be well tolerated with consistent safety outcomes, supporting the favorable benefit-risk profile of Kesimpta in RMS2 Basel, April 17, 2024 – Novartis today announced data from the ALITHIOS open-label extension study showing sustained efficacy of first-line, continuous Kesimpta® (ofatumumab) treatment for up to six years in recently diagnosed – defined as s

Idorsia publishes a Financial Status required for an upcoming bondholder meeting17.4.2024 07:00:00 CEST | Press release

Ad hoc announcement pursuant to Art. 53 LR Unaudited Financial Status as of March 31, 2024, required for an upcoming bondholder meeting, now available on the company websiteBondholder meeting now planned for early May as the company continues to engage with bondholders Allschwil, Switzerland – April 17, 2024 Idorsia Ltd (SIX: IDIA) today announced that its Unaudited Financial Status as of March 31, 2024, required for an upcoming bondholder meeting is available on the company website at the following link: http://www.idorsia.com/investors/financial-information Idorsia continues to engage with bondholders on options and terms regarding the repayment of the convertible bond maturing on July 17, 2024 (ISIN: CH0426820350). As a result, the bondholder meeting initially contemplated for April 30, 2024, is expected to take place shortly thereafter. André C. Muller, Chief Financial Officer, commented: “We have had many interactions with our bondholders in the past week. We are finalizing our pr

Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis17.4.2024 07:00:00 CEST | Press release

New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis Data support frexalimab as a potential first-in-class, high-efficacy, non-lymphocyte depleting treatment for relapsing multiple sclerosis96% of participants receiving high-dose intravenous frexalimab had no new Gd+ T1 lesions and an annualized relapse rate of 0.04 after 48 weeksSanofi has initiated global phase 3 studies of frexalimab in relapsing MS and non-relapsing secondary progressive MS Paris, April 17, 2024. Sanofi’s CD40L antibody, frexalimab, demonstrated sustained reduction of disease activity and favorable tolerability after nearly one year in participants with relapsing multiple sclerosis. These data will be presented today at the American Academy of Neurology (AAN) 2024 Annual Meeting in Denver, Colorado, US. Results from the 12-week double-blind study period were previously published in The New England Journal of Medicine. Patrick Vermersch, MD, PhD University of Lille,

TokenEx and IXOPAY to Merge, Enabling Merchants to Optimize the Use of Multiple Payment Processors17.4.2024 06:00:00 CEST | Press release

Payments Optimization Platform for Global Commerce Delivers Omnichannel Tokenization, Payments Orchestration, and Card Lifecycle Management TULSA, Okla. and VIENNA, Austria, April 17, 2024 (GLOBE NEWSWIRE) -- TokenEx, the leading cloud tokenization provider, and IXOPAY, the leading independent payments orchestration platform, today are announcing their definitive agreement to merge, creating a new leader in global payments optimization. The combined company will be called IXOPAY, a TokenEx Company, and Marc Olesen will lead the combined organization as CEO. Customers will benefit from a comprehensive platform that enables increased authorization rates and decreased interchange fees for merchants, along with PCI-certified secure payment data. This merger brings together the strengths of TokenEx’s expertise in tokenization of payment data, and IXOPAY's world-class payments orchestration, including transaction routing & reconciliation capabilities. “This merger marks a significant milesto

Convening Notice for Annual General Meeting and Extraordinary General Meeting of Shareholders17.4.2024 02:00:00 CEST | Press release

Convening Notice for Annual General Meeting and Extraordinary General Meeting of Shareholders MILLICOM INTERNATIONAL CELLULAR S.A. Registered Address: 2, Rue du Fort Bourbon L-1249 Luxembourg, Grand Duchy of Luxembourg – R.C.S. Luxembourg: B 40.630 – I. NOTICE The annual general meeting (“AGM”) and subsequent extraordinary general meeting (“EGM”) of the shareholders of MILLICOM INTERNATIONAL CELLULAR S.A. (“Millicom” or the “Company”) is hereby convened to be held at Hotel Le Royal, 12 Bd Royal, 2449 Luxembourg on Thursday, May 23, 2024, at 11:00 a.m. Central European Time ("CET"). To attend the AGM and EGM or vote by proxy, please follow the instructions in section IV: “Right to participate at the AGM and the EGM”. The AGM and EGM will consider and vote on the agenda points listed below. Please refer to section IX: “Notes to the Agenda Points of the AGM and EGM” to find detailed information about these proposals. II. AGENDA AGM To elect the chair of the AGM and to empower the chair of

HiddenA line styled icon from Orion Icon Library.Eye